Global Preventative Medicine Demand And mRNA Pipelines Will Transform Healthcare

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
11 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$121.78
78.1% undervalued intrinsic discount
06 Aug
US$26.71
Loading
1Y
-67.2%
7D
-16.9%

Author's Valuation

US$121.8

78.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 1.09%

Shared on30 Apr 25
Fair value Decreased 3.15%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 43%

AnalystHighTarget has increased future PE multiple from 84.2x to 120.1x.

Shared on16 Apr 25
Fair value Decreased 0.66%

AnalystHighTarget made no meaningful changes to valuation assumptions.